Back in May 2015 we posted about the use of vaginal estrogen for restoring vaginal elasticity and function in the menopausal woman. The post was titled, Vaginal estrogen poses no apparent cancer risk, and addressed women’s concerns about the safety of vaginal estrogen. The post also explains the decline of vaginal use and function during menopause and why estrogen is recommended.
In the years since, the topic continues to surface often when menopausal patients present for the treatment of painful sex, burning, and other urogenital complaints.
This week (8/21/2017), a publication in Menopause reaffirmed the same: analysis indicated “vaginal estrogen therapy use was not” associated with “any increased cardiovascular or cancer risk.” Researchers found that “among postmenopausal women ages 50 to 79 with an intact uterus, the risk of invasive breast cancer, colorectal cancer, endometrial cancer, stroke, and pulmonary embolism or deep vein thrombosis was no greater when compared with non-users.” Meanwhile, the research “showed no significant risk differences between estrogen users and non-users for individual or overall global index event (GIE) risks among women who had previously undergone a hysterectomy either.”
With women living much longer than estrogen production was design to be, such validation is imperative for vaginal estrogen IS the cornerstone of reversing menopausal vaginal atrophy (unless medically contraindicated).